Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
- Conditions
- Hepatitis C Infection With HIV Co-Infection
- Interventions
- Drug: LDV/SOF
- Registration Number
- NCT02457611
- Lead Sponsor
- Gilead Sciences
- Brief Summary
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with acute genotype 1 or 4 hepatitis C virus (HCV) and chronic human immunodeficiency virus (HIV)-1 co-infection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26
- Acute, untreated, hepatitis C infection, genotype 1 or 4, with an estimated duration less than 24 weeks
- Confirmed HIV-1 infection
- CD4 T cell count >200/μL for individuals receiving antiretroviral therapy (ART), CD4 T cell count > 500/μL at screening for individuals without ART
- Use of two effective contraception methods if female of childbearing potential or sexually active male with female partner
Key
- Pregnant or nursing female or male with pregnant female partner
- Chronic liver disease of a non HCV etiology
- Coinfection with hepatitis B virus (HBV)
- Treatment with any investigational drug or device within 60 days of the screening visit.
- History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description LDV/SOF LDV/SOF LDV/SOF FDC for 6 weeks
- Primary Outcome Measures
Name Time Method Percentage of Participants With Sustained Virologic Response 12 Weeks After Completion of Treatment (SVR12) Posttreatment Week 12 SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event Up to 6 weeks
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Sustained Virologic Response 4 Weeks After Discontinuation of Study Treatment (SVR4) Posttreatment Week 4 SVR4 was defined as HCV RNA \< LLOQ 4 weeks after the last dose of study drug.
Percentage of Participants With HCV RNA < LLOQ on Treatment Weeks 2, 4, and 6 Change From Baseline in HCV RNA at Weeks 2, 4, and 6 Baseline; Weeks 2, 4, and 6 Percentage of Participants With Virologic Failure Up to Posttreatment Week 12 Virologic failure was defined as:
* On-treatment virologic failure
* confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ, while on treatment (ie, breakthrough),
* confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment (ie, rebound),
* HCV RNA persistently ≥ LLOQ through end of treatment (ie, nonresponse)
* Relapse
* HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurementChange in HIV RNA From Day 1 to End of Treatment as Assessed by Proportion of Participants Who Had Confirmed HIV Virologic Rebound During the Study. Day 1; Week 6 Participants with HIV virologic rebound was defined as participants with at least two HIV RNA ≥ 400 copies/mL at 2 consecutive post-baseline visits which are at least 2 weeks apart based on actual dates.
Percentage of Participants That Maintain HIV-1 RNA < 50 Copies/mL While on HCV Treatment and at Posttreatment Week 4 Weeks 2, 4, 6, and Posttreatment Week 4 Percent Change From Baseline in CD4 T-cell Count at the End of Treatment and at Posttreatment Week 4 Baseline; Week 6; Posttreatment Week 4